PDAPP; YFP double transgenic mice: A tool to study amyloid-β associated changes in axonal, dendritic, and synaptic structures

Journal of Comparative Neurology

Volumn 456, Issue 4, 2003, Pages 375-383

  Brendza, Robert P ^a   O'Brien, Cara ^a   Simmons, Kelly ^a   McKeel, Daniel W ^a   Bales, Kelly R ^b   Paul, Steven M ^b,c   Olney, John W ^a   Sanes, Joshua R ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Fluorescent protein; Neuritic dystrophy; Silver stain

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; YELLOW FLUORESCENT PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENDRITE; ELECTRON MICROSCOPY; GLIA CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; SILVER STAINING; SYNAPSE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BACTERIAL PROTEINS; BRAIN; DENDRITES; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; LUMINESCENT PROTEINS; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; NEURITES; NEURONS; PRESYNAPTIC TERMINALS; SILVER STAINING; SYNAPTIC VESICLES;

EID: 0037450356     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.10536     Document Type: Article

References (33)

1. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT. 2001. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7:369-372.
2. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. 1997. Lack of apolipoprotein E dramatically reduces amyloid betapeptide deposition. Nat Genet 17:263-264.
3. Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM. 1998. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55:326-335.
4. Braak H, Braak E. 1991. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1:213-216.
5. Buckley K, Kelly RB. 1985. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol 100:1284-1294.
6. Cavalieri B. 1966. Geometria degli indivisibili. Torino: Unione Tipografico.
7. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. 1998. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51:S2-17; discussion S65-67.
8. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM. 2002. Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81:229-236.
9. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR. 2000. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28:41-51.
10. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. 1995. Alzheimertype neuropathology in transgenic mice overexpressing V717F betaamyloid precursorprotein. Nature 373:523-527.
11. Geppert M, Sudhof TC. 1998. RAB3 and synaptotagmin: the yin and yang of synaptic membrane fusion. Annu Rev Neurosci 21:75-95.
12. Gotz J, Chen F, Barmettler R, Nitsch RM. 2001. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276:529-534.
13. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. 2000a. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97:2892-2897.
14. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT. 2000b. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47:739-747.
15. Huttner WB, Schiebler W, Greengard P, De Camilli P. 1983. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol 96:1374-1388.
16. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. 1997. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17:7053-7059.
17. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM. 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24:751-762.
18. Ishimaru MJ, Ikonomidou C, Tenkova TI, Der TC, Dikranian K, Sesma MA, Olney JW. 1999. Distinguishing excitotoxic from apoptotic neuro-degeneration in the developing rat brain. J Comp Neurol 408:461-476.
19. Jaffar S, Counts SE, Ma SY, Dadko E, Gordon MN, Morgan D, Mufson EJ. 2001. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp Neurol 170:227-243.
20. Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, Stanley HE, Hyman BT. 1999. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci USA 96:5274-5279.
21. Le R, Cruz L, Urbanc B, Knowles RB, Hsiao-Ashe K, Duff K, Irizarry MC, Stanley HE, Hyman BT. 2001. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J Neuropathol Exp Neurol 60:753-758.
22. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. 2000. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402-405.
23. Masliah E, Rockenstein E. 2000. Genetically altered transgenic models of Alzheimer's disease. J Neural Transm Suppl 59:175-183.
24. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. 1996. Comparison of neurodegenerative pathology in transgenic mice overexpressing VT17F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 16:5795-5811.
25. Masliah E, Sisk A, Mallory M, Games D. 2001. Neurofibrillary pathology in transgenic mice overexpressing V717F beta- amyloid precursor protein. J Neuropathol Exp Neurol 60:357-368.
26. Matthew WD, Tsavaler L, Reichardt LF. 1981. Identification of a synaptic vesicle-specific membrane protein with a wide distribution in neuronal and neurosecretory tissue. J Cell Biol 91:257-269.
27. Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, Berg L. 1996. Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46:707-719.
28. Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
29. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G. 1998. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70:2212-2215.
30. Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Okamoto K, Shoji M. 2000. Impaired neurotransmitter systems by Abeta amyloidosis in APPsw transgenic mice overexpressing amyloid beta protein precursor. Neurosci Lett 292:155-158.
31. West MJ. 1993. New stereological methods for counting neurons. Neurobiol Aging 14:275-285.
32. Wiedenmann B, Franke WW. 1985. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell 41:1017-1028.
33. Wozniak DF, Brosnan-Watters G, Nardi A, McEwen M, Corso TD, Olney JW, Fix AS. 1996. MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning. Brain Res 707:165-179.